02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
07:00 , Oct 27, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer Patient sample, cell culture and mouse studies suggest inhibiting KDM6B could help treat hepatocellular carcinoma (HCC). In patients, high tumor KDM6B expression correlated with poor survival. In human HCC cell lines, shRNA...
07:00 , Sep 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) Lysine-specific demethylase 6A (KDM6A; UTX); KDM6B (JMJD3) Cell culture and mouse studies suggest inhibiting JMJD3 could help treat T cell acute...
07:00 , Sep 11, 2014 |  BC Innovations  |  Targets & Mechanisms

A chromatin target for ALL

A New York University School of Medicine - GlaxoSmithKline plc collaboration has shown that an inhibitor of the chromatin regulator JMJD3 could help treat T cell acute lymphoblastic leukemia. 1 As JMJD3 is upregulated and...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Protagen sales and marketing update

Protagen launched ADx SSc Multilisa in the EU and North America to research scleroderma. The qualitative ELISA-based test kit uses Protagen’s SeroTag biomarker platform to detect autoantibody levels of topoisomerase I (TOP1) , centromere protein...
07:00 , Aug 9, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Jumonji domain containing 3 (JMJD3; KDM6B); lysine-specific demethylase 6A (KDM6A; UTX) An in vitro and cell culture study identified a compound that...
07:00 , Aug 9, 2012 |  BC Innovations  |  Cover Story

Hitting histone demethylases

A team from GlaxoSmithKline plc and the Structural Genomics Consortium has identified the first selective and potent histone demethylase inhibitor and shown it dampens the macrophage inflammatory response. 1 The pharma now is exploring the...